msr1  (Bioss)

Journal: Anticancer research

Article Title: Cryoablation for Malignant Bone and Soft Tissue Tumors and Histological Assessment of Ablated Tumors.

doi: 10.21873/anticanres.17372

Figure Lengend Snippet: Figure 4. Patient 1 in Table III. A) Frontal x-ray. B) Lateral x-ray. C) T2-weighted fat-suppressed coronal magnetic resonance imaging (MRI). D) Axial MRI. E) Positron emission tomography-computed tomography. F) Postoperative x-ray. G) CT-guided cryoablation. H) H&E stain. I-N) Immunostaining for anti-CD4 (I), anti-CD8 (J), anti-CD68 (K), anti-CD16 (L), anti-CD204 (M), and anti-IDO (N).

Article Snippet: Slides were then incubated overnight at room temperature with primary antibodies specific for CD68 (monoclonal mouse anti-CD68, diluted 1:50, catalog M0876; Dako, Glostrup, Denmark), CD4 (monoclonal mouse anti-CD4, diluted 1:50, catalog M7310; Dako), CD8 (monoclonal mouse anti-CD3, diluted 1:50, catalog N1592; Dako), CD16 (polyclonal rabbit anti-CD16, diluted 1:300, catalog 16559-1-AP; Proteintech, Rosemont, IL, USA), CD204 (monoclonal mouse anti-CD204, diluted 1:200, catalog KMUMA01; COSMO BIO Co., Tokyo, Japan), indoleamine 2,3-dioxygenase (IDO) (monoclonal mouse anti-IDO, diluted 1:250, catalog MAB60302; R&D Systems, Minneapolis, MN, USA), and CD47 (polyclonal sheep anti-CD47, diluted 1:200, catalog AF4670; R&D Systems).

Techniques: Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Staining, Immunostaining

Journal: Anticancer research

Article Title: Cryoablation for Malignant Bone and Soft Tissue Tumors and Histological Assessment of Ablated Tumors.

doi: 10.21873/anticanres.17372

Figure Lengend Snippet: Figure 5. Patient 2 in Table III. A) Frontal x-ray. B) Dynamic contrast-enhanced T1-weighted axial magnetic resonance imaging (MRI) before cryoablation. C) MRI after cryoablation. D) Postoperative x-ray. E) Computed tomography-guided cryoablation. F) H&E stain. G-L) Immunostaining for anti-CD4 (G), anti-CD8 (H), anti-CD68 (I), anti-CD16 (J), anti-CD204 (K), and anti-IDO (L).

Article Snippet: Slides were then incubated overnight at room temperature with primary antibodies specific for CD68 (monoclonal mouse anti-CD68, diluted 1:50, catalog M0876; Dako, Glostrup, Denmark), CD4 (monoclonal mouse anti-CD4, diluted 1:50, catalog M7310; Dako), CD8 (monoclonal mouse anti-CD3, diluted 1:50, catalog N1592; Dako), CD16 (polyclonal rabbit anti-CD16, diluted 1:300, catalog 16559-1-AP; Proteintech, Rosemont, IL, USA), CD204 (monoclonal mouse anti-CD204, diluted 1:200, catalog KMUMA01; COSMO BIO Co., Tokyo, Japan), indoleamine 2,3-dioxygenase (IDO) (monoclonal mouse anti-IDO, diluted 1:250, catalog MAB60302; R&D Systems, Minneapolis, MN, USA), and CD47 (polyclonal sheep anti-CD47, diluted 1:200, catalog AF4670; R&D Systems).

Techniques: Magnetic Resonance Imaging, Computed Tomography, Staining, Immunostaining

Journal: Anticancer research

Article Title: Cryoablation for Malignant Bone and Soft Tissue Tumors and Histological Assessment of Ablated Tumors.

doi: 10.21873/anticanres.17372

Figure Lengend Snippet: Figure 7. Patient 6 (immunostaining: areas 1, 2, 3). Numbers correspond to squares in Figure 6K. Area 1 is necrotic. Area 2 is the border. Area 3 is remnant tumor. Immunostains: A-C, anti-CD4; D-F, anti-CD8; G-I, anti-CD68; J-L, anti-CD16; M-O, anti-CD204; P-R, anti-IDO; S-U, anti- beta-catenin.

Article Snippet: Slides were then incubated overnight at room temperature with primary antibodies specific for CD68 (monoclonal mouse anti-CD68, diluted 1:50, catalog M0876; Dako, Glostrup, Denmark), CD4 (monoclonal mouse anti-CD4, diluted 1:50, catalog M7310; Dako), CD8 (monoclonal mouse anti-CD3, diluted 1:50, catalog N1592; Dako), CD16 (polyclonal rabbit anti-CD16, diluted 1:300, catalog 16559-1-AP; Proteintech, Rosemont, IL, USA), CD204 (monoclonal mouse anti-CD204, diluted 1:200, catalog KMUMA01; COSMO BIO Co., Tokyo, Japan), indoleamine 2,3-dioxygenase (IDO) (monoclonal mouse anti-IDO, diluted 1:250, catalog MAB60302; R&D Systems, Minneapolis, MN, USA), and CD47 (polyclonal sheep anti-CD47, diluted 1:200, catalog AF4670; R&D Systems).

Techniques: Immunostaining

Journal: Anticancer research

Article Title: Cryoablation for Malignant Bone and Soft Tissue Tumors and Histological Assessment of Ablated Tumors.

doi: 10.21873/anticanres.17372

Figure Lengend Snippet: Figure 8. Patient 6 (immunostaining: areas 4-7). Numbers correspond to squares in Figure 6K. Area 4 is necrotic. Area 5 is the border on the necrotic side. Area 6 is the border on the tumor side. Area 7 is remnant tumor. Immunostains: A-D, anti-CD4; E-H, anti-CD8; I-L, anti-CD68; M- P, anti-CD16; Q-T, anti-CD204; U-X, anti-IDO; Y, Z, α, β, anti-beta catenin.

Article Snippet: Slides were then incubated overnight at room temperature with primary antibodies specific for CD68 (monoclonal mouse anti-CD68, diluted 1:50, catalog M0876; Dako, Glostrup, Denmark), CD4 (monoclonal mouse anti-CD4, diluted 1:50, catalog M7310; Dako), CD8 (monoclonal mouse anti-CD3, diluted 1:50, catalog N1592; Dako), CD16 (polyclonal rabbit anti-CD16, diluted 1:300, catalog 16559-1-AP; Proteintech, Rosemont, IL, USA), CD204 (monoclonal mouse anti-CD204, diluted 1:200, catalog KMUMA01; COSMO BIO Co., Tokyo, Japan), indoleamine 2,3-dioxygenase (IDO) (monoclonal mouse anti-IDO, diluted 1:250, catalog MAB60302; R&D Systems, Minneapolis, MN, USA), and CD47 (polyclonal sheep anti-CD47, diluted 1:200, catalog AF4670; R&D Systems).

Techniques: Immunostaining

Journal: Frontiers in Pharmacology

Article Title: The mechanism of low molecular weight fucoidan-incorporated nanofiber scaffolds inhibiting oral leukoplakia via SR-A/Wnt signal axis

doi: 10.3389/fphar.2024.1397761

Figure Lengend Snippet: Effect of LMWF on the SR-A/Wnt signaling axis and related gene expression. (A–E) After different treatments, the expression of mRNA for SR-A, CTNNB1, FZD6, TCF4, and AXIN1. (F) Representative protein expression bands for SR-A, CTNNB1, FZD6, TCF4, AXIN1, and β-actin. (G–K) Relative expression levels of SR-A, CTNNB1, FZD6, TCF4, and AXIN1 proteins compared to β-actin. Data were expressed as the means ± SD. *** p < 0.001, ** p < 0.01 and * p < 0.05 vs. DOK negative group.

Article Snippet: The following reagents were used: RNAi-interfering lentivirus (LV-EGFP-RNAi) and negative control virus (LveGFP) were constructed by Gikai Gene Chemistry Technology Ltd. (Shanghai, China); CCK-8 kit was purchased from GLPBIO Co., Ltd. (Montclair, CA, United States); Annexin-V-FITC/PI Apoptosis Kit and Annexin V-APC/PI Apoptosis Kit were purchased from Wuhan Jingrui Biotechnology Co., Ltd. (Wuhan, Hubei, China); TRIzol kit was purchased from Sigma-Aldrich Co., Ltd. (St. Louis, Missouri, United States); SYBR PreMix Ex TaqTMII, PrimeScriptTM RT kits were purchased from Takara Biotech Co., Ltd. (Kusatsu, Shiga, Japan); Primers were designed and synthesized by Shanghai Biotechnology Co; β-catenin, TCF4, and Frizzled 6 antibodies were purchased from Abcam (Cambridge, United Kingdom); β-actin, SR-A antibodies was purchased from Proteintech (Chicago, United States); AXIN1 antibody was purchased from Cell Signaling Technology (Danvers, MA, United States); Artificial saliva and Wnt/β-catenin signaling pathway inhibitor IWR-1 were purchased from MedChemExpress (Monmouth County, New Jersey, United States); PLCL (50:50, Mn:300000) was purchased from Shenzhen Maiqi Biomaterials Co; Hexafluoroisopropanol (HFIP) was purchased from Shanghai Darui Fine Chemical Co; DMMB Taylor’s Blue was purchased from Shanghai Maclean Biochemical Technology Co; Poly-L-lysine Solution was purchased from Beijing Solexpro Technology Co; L-polylysine (PLL) was purchased from Thermo Fisher Scientific (Massachusetts, United States).

Techniques: Gene Expression, Expressing

Journal: Heliyon

Article Title: Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG)

doi: 10.1016/j.heliyon.2024.e27510

Figure Lengend Snippet: Evaluation of the impact of MSR1 and BIRC5 on LGG cells. (A) The volcano map showed the differences in expression of each immune-related gene between LGG and GBM. The results showed that MSR1 and BIRC5 were both differentially expressed between LGG and GBM (p < 0.0001, |LogFC|>1.5). (B) Western blot analysis was performed to quantitate MSR1 and BIRC5 protein levels in NHA, SW1088, and SW1783 cells. *P < 0.05. (C) Quantitative RT-PCR analysis of MSR1 and BIRC5 in NHA, SW1088, and SW1783 cells. Expression was normalized against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression. *P < 0.05. (D) Efficiency of MSR1 knockdown after transfection of cells with three shMSR1. (E) Flow cytometry was used to evaluate changes in apoptosisin SW1088 cells in response to YM155 treatment and shMSR1. (F) Edu assay showed that YM155 and shMSR1 treatment significantly reduced proliferation of SW1088 and SW1783 cells. (G) Flow cytometry was used to evaluate changes in cell cycle of SW1088 cells in response to YM155 treatment.

Article Snippet: Afterwards, the membranes will be subjected to incubation at a temperature of 4 °C with particular primary antibodies, which consist of GAPDH (1:20,000, Proteintech), MSR1 (1:1,000, CST), and BIRC5 (1:500, Proteintech).

Techniques: Expressing, Western Blot, Quantitative RT-PCR, Knockdown, Transfection, Flow Cytometry, EdU Assay